Targets › SOD2
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.
Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems. (UniProt, P04179)
Open in Phaseline: the race on SOD2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| NRG Oncology | MnSOD Mimetic BMX-001 Manganese superoxide dismutase (SOD2) mimetic; neutralizes free radicals and reactive oxyg | SOD2 | Phase 2 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Jan 2027 |
| West China Hospital | superoxide dismutase skin spray antioxidant enzyme that catalyzes the dismutation of superoxide radicals | SOD1, SOD2, SOD3 | Phase 2 | Radiation-induced Dermatitis | Jan 2027 |
| The University of Texas Health Science Center at San Antonio | Avasopasem Mitochondrial superoxide dismutase (SOD2) mimetic; superoxide scavenger | SOD2 | Phase 1 | Breast Cancer Metastatic | Oct 2027 |
Radiation-induced Dermatitis (1) Breast Cancer Metastatic (1) Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)
small molecule (2), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.